E
ENZ

Ergoteles’s Enzo Biochem, Inc. ENZ Stock Holding History

Ergoteles’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-21,032
Closed -$68K – 1696
2021
Q4 		$68K Sell
21,032
-156,016
-88% -$532K ﹤0.01% 1173
2021
Q3 		$627K Sell
177,048
-15,852
-8% -$52.9K 0.02% 500
2021
Q2 		$611K Buy
+192,900
New +$607K 0.01% 711

Other funds holding ENZ

HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCA
VIEX Capital Advisors Sunny Isles Beach, Florida $30.9M AUM 55.48% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Ergoteles's ENZ Position: Q1 2022 in Review

Ergoteles sold out of Enzo Biochem, Inc. (ENZ) in Q1 2022, closing a stake of 21,032 shares — an estimated $68K sold.

Ergoteles first reported a position in ENZ in Q2 2021 and held it in 3 quarters. The position peaked at $627K in Q3 2021. 51 funds tracked by Wall St. Rank hold ENZ as of Q1 2022.

  • Ergoteles reported no remaining Enzo Biochem, Inc. position as of Q1 2022 after selling out during the quarter.
  • Ergoteles sold 21,032 Enzo Biochem, Inc. shares in Q1 2022, an estimated $68K.
  • Ergoteles first reported a position in Enzo Biochem, Inc. in Q2 2021 and held it in 3 quarters.
  • Ergoteles's Enzo Biochem, Inc. position peaked at $627K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q1 2022.

Based on Ergoteles's 13F filing for Q1 2022, filed 13 May 2022.